Neurocrine Biosciences NBIX Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Based on the most recent quarter.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's debt-to-equity?
- Neurocrine Biosciences (NBIX) reported debt-to-equity of 0.1× in Q1 2026.
- How has Neurocrine Biosciences's debt-to-equity changed year-over-year?
- Neurocrine Biosciences's debt-to-equity decreased by 30.1% year-over-year, from 0.2× to 0.1×.
- What is the long-term trend for Neurocrine Biosciences's debt-to-equity?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's debt-to-equity has grown at a 16.1% compound annual growth rate (CAGR), from 0.4× to 0.7×.
- What does debt-to-equity mean?
- How much debt the company carries for every dollar of shareholder equity.
- How do you interpret debt-to-equity?
- Lower is generally safer, but moderate leverage can boost returns. Read in the context of cash-flow stability — a utility tolerates more debt than a cyclical. Negative equity makes the ratio meaningless and it is suppressed there.
- How does debt-to-equity compare across companies?
- Comparable within an industry; capital structures differ sharply across sectors. Not meaningful for banks.